By continuing to browse Regimens of levofloxacin, initially involving total daily doses of 250 mg to 500 mg, but more recently regimens involving 750 mg doses, have been shown to be safe and effective.

evaluated allergic reactions associated with oral drug use in a large database of spontaneous adverse drug reaction reports.There is accumulating data suggesting that fluoroquinolones are an important risk factor for Sensory or sensorimotor axonal polyneuropathy affecting both small and large axons has been reported in a minority of patients during treatment with fluoroquinolones, resulting in paresthesias, hypoesthesias, dysesthesias, and weakness.During treatment with a fluoroquinolone, patients may experience photosensitivity or phototoxicity, manifested by an exaggerated sunburn reaction in locations exposed to sunlight or artificial ultraviolet light. A summary of prospective, randomized, blinded studies of lower and upper respiratory tract infections is shown in There is a large evidence base for the use of levofloxacin in the treatment of community-acquired pneumonia, leading experts to recommend it as first-line treatment for patients with comorbidities (e.g. Please check you selected the correct society from the list and entered the user name and password you use to log in to your society website.Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicil-lin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trialLevofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label studyApplication of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapySurveillance of resistance in bacteria causing community-acquired respiratory tract infectionsWorldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Levofloxacin: an updated review of its use in the treatment of bacterial infectionsLevofloxacin: a review of its use in the treatment of bacterial infections in the United StatesLevofloxacin: a review of its use as a highdose, short-course treatment for bacterial infectionOpen-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluidPharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous dosesDouble-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteersA randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infectionsSafety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteersEffects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjectsConcentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopyPenetration of levofloxacin into lung tissue after oral administration to subjects undergoing lung biopsy or lobectomySteady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjectsSteady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adultsIntrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjectsPharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unitPenetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral doseUse of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitisUrinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of A population pharmacokinetic analysis of the penetration of the prostate by levofloxacinPharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymorePharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and menPharmacodynamics of intravenous ciprofloxacin in seriously ill patientsFluoroquinolone AUIC break points and the link to bacterial killing rates.